This is a "connection" page, showing publications co-authored by Carol Sherman and Gerard Silvestri.
Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. Transl Lung Cancer Res. 2012 Jun; 1(2):96-8.
The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer. 2012 May; 76(2):131-7.
Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis. J Thorac Oncol. 2006 Feb; 1(2):112-9.
The role of radiotherapy and chemotherapy for curative management of medically inoperable and stage III nonsmall cell lung cancer, and radiotherapy for palliation of symptomatic disease. Respir Care Clin N Am. 2003 Jun; 9(2):163-90.
Caring for the dying patient with lung cancer. Chest. 2002 Sep; 122(3):1028-36.
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010 Oct; 54(5):483-9.
Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn. 2003 Nov; 5(4):237-42.